Journal
ACG CASE REPORTS JOURNAL
Volume 4, Issue -, Pages -Publisher
AMER COLL GASTROENTEROLOGY
DOI: 10.14309/crj.2017.57
Keywords
-
Categories
Ask authors/readers for more resources
Nivolumab is a novel chemotherapy currently approved for the treatment of multiple metastatic malignancies. This class of therapy, known as immune checkpoint inhibitors, is notable for an autoimmune-related adverse event profile. Diarrhea and colitis are common gastrointestinal adverse events, however, upper gastrointestinal events are rarely reported. We present a case of nivolumab-associated esophagitis and gastritis that has yet to be reported in the published literature.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available